Mark Batshaw

Mark Levitt Batshaw (born 19 September 1945) is a Canadian-born physician, medical researcher and academic administrator.[1] He is a professor in the department of pediatrics and an associate dean at the George Washington University School of Medicine & Health Sciences and is the physician-in-chief and chief academic officer at the Children’s National Medical Center in Washington, D.C. He is known for his research into urea cycle disorders and gene therapy, and is the author of the classic textbook "Children with Disabilities".[2]

Mark Batshaw
Born (1945-09-19) 19 September 1945
Montreal, Canada
Alma materUniversity of Pennsylvania, University of Chicago
Known forStudy of urea cycle disorders
Scientific career
FieldsPediatrics
InstitutionsChildren's National Medical Center, Children’s Hospital of Philadelphia, Kennedy Krieger Institute

Biography

Batshaw was born in Montreal, Canada, in 1945 and is a United States citizen. His father, Manuel G. Batshaw, was a social worker. Batshaw manifested dyslexia and attention deficit hyperactivity disorder as a child at a time where there were limited special education services or medication for treatment. It was this experience that led him to the fields of developmental disabilities and genetics.[3]

Batshaw received his M.D. from the University of Chicago Pritzker School of Medicine in 1971, performed his pediatric residency at The Hospital for Sick Children, University of Toronto, and his clinical fellowship at the Kennedy Krieger Institute, Johns Hopkins Hospital.

From 1988-1998, Batshaw was Physician-in-Chief of the Children’s Seashore House at the Children’s Hospital of Philadelphia. He was Chairman of Pediatrics at the George Washington University School of Medicine & Health Sciences from 1998-2014 and as of 2017 is the Associate Dean for Academic Affairs at the university, and Chief Academic Officer and Physician-in-Chief at Children's National Medical Center. He has served as president of both the Society for Inherited Metabolic Disorders and the American Pediatric Society.[4]

He and his wife Karen are the parents of three children.

Research

During his clinical fellowship at the Kennedy Krieger Institute, Batshaw and his colleague Saul Brusilow developed a successful treatment for a fatal urea cycle disorder.[5][6][7] The treatment, involving sodium phenylbutyrate and glycerol phenylbutyrate, is still in use.[8]

In 1988, Batshaw moved from Hopkins to the University of Pennsylvania where he began a collaboration with James Wilson. They developed an adenovirus vector and started a gene therapy clinical trial that resulted in the death of a patient, Jesse Gelsinger, in 1999 and a subsequent slowdown of the development of gene therapy.[9] In the past decade, the field has recovered[10][11] and Wilson and Batshaw’s teams have developed an adeno-associated virus vector that has been successful in preclinical studies of an animal model of urea cycle disorders.[12]

gollark: There were, according to the Wikipedia page, actually some security flaws found.
gollark: According to Wikipedia (praise be) the AMD one has an onboard "micro-OS" too, and the (compiled) code was dumped and researched a bit.
gollark: The AMD one is on the actual CPU.
gollark: No, you're right, it is on chipset.
gollark: No, it's on-CPU, not the chipset.

References
  1. "Challenges abound as researchers search for rare disease treatments". Retrieved 14 October 2017.
  2. Brookes Publishing author biography, Mark Batshaw, M.D.
  3. Kelly, John (December 2, 2004). "Early Training for a Thoughtful Doctor". Washington Post. Retrieved 10 September 2017.
  4. https://www.aps-spr.org/aps/newsletters/2016/issue2/#03
  5. Brusilow, Saul; Tinker J; Batshaw ML (8 February 1980). "Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis". Science. AAAS. 207 (4431): 659–61. doi:10.1126/science.6243418. PMID 6243418.
  6. Batshaw, Mark L.; Brusilow, S.; Waber, L.; Blom, W.; Brubakk, A.M.; Burton, B.K.; Cann, H.M.; Kerr, D.; Mamunes, P.; Matalon, R.; Myerberg, D.; Schafer, I.A. (10 June 1982). "Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion". N Engl J Med. 306 (23): 1387–92. doi:10.1056/nejm198206103062303. PMID 7078580.
  7. Brusilow, Saul W.; Danney M; Waber LJ; Batshaw M; Burton B; Levitsky L; Roth K; McKeethren C; Ward J (21 June 1984). "Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis". N Engl J Med. 310 (25): 1630–4. doi:10.1056/nejm198406213102503. PMID 6427608.
  8. Batshaw, M. L.; MacArthur, R. B.; Tuchman, M. (2001). "Alternative pathway therapy for urea cycle disorders: twenty years later". J. Pediatr. 138 (1 Suppl): S46–S54, discussion S54–S55. doi:10.1067/mpd.2001.111836. PMID 11148549.
  9. The Biotech Death of Jesse Gelsinger by Sheryl Gay Stolberg, The New York Times Magazine, November 28, 1999
  10. Gene Therapy Emerges From Disgrace to Be the Next Big Thing, Again by Carl Zimmer August 13, 2013 Wired
  11. Gene therapy's slow rebirth, InnovationDistrict, May 30, 2017
  12. Wang, L.; Bell, P.; Morizono, H.; He, Z.; Pumbo, E.; Yu, H.; White, J.; Batshaw, M.L.; Wilson, J.M. (April 2017). "AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice". Mol Genet Metab. 120 (4): 299–305. doi:10.1016/j.ymgme.2017.02.011. PMC 5423267. PMID 28283349.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.